1. Targeting Macrophages
========================

1.1. Targeting Monocytes and Macrophages in Inflammation
--------------------------------------------------------

Monocytes and macrophages have a strong regulatory effect on inflammation \[[@B1-membranes-05-00228]\] owing to the expression of a range of cytokines, including TNF \[[@B2-membranes-05-00228],[@B3-membranes-05-00228]\], interleukin-1 (IL-1) \[[@B3-membranes-05-00228]\], IL-6 \[[@B4-membranes-05-00228]\], TWEAK \[[@B5-membranes-05-00228]\] and B-cell activation factor \[[@B6-membranes-05-00228]\]. All of these cytokines are single targets for registered or experimental therapy with monoclonal antibodies that bind to and neutralize the effect of the cytokines. A more potent approach would be to inhibit the production of these cytokines at the source by modulating macrophage expression pattern through overall modification of macrophage polarization \[[@B7-membranes-05-00228]\]. This may also inhibit paracrine signaling of released cytokines that might be difficult to neutralize by a therapeutic antibody due to the cell contacts. In addition, modulating macrophage phenotype may also reduce macrophage-mediated tissue damage (hemophagocytosis) in sepsis and in the macrophage activation syndrome \[[@B8-membranes-05-00228],[@B9-membranes-05-00228]\].

1.2. Targeting Macrophages in Cancer
------------------------------------

In cancer, tumor-associated macrophages are recruited to the tumor stroma where they sustain tumor-growth by (1) the removal of cell debris; (2) stimulation of neovascularization and tissue re-modeling; (3) production of growth factors; and (4) immunosuppression. Furthermore, tumor-associated macrophages contribute to metastasis by promoting tumor cell extravasation \[[@B10-membranes-05-00228],[@B11-membranes-05-00228]\]. The tumor-supportive macrophage population is therefore an attractive target for therapies inhibiting tumor growth, in analogy with anti-angiogenic therapy that indirectly hits the tumors As an alternative to eradication with a targeted toxin, macrophages might instead be targeted with small molecule drugs to reprogram the macrophages to a repolarized state where they suppress rather than stimulate tumor growth \[[@B11-membranes-05-00228]\].

1.3. Targeting Macrophages in Infectious and Lysosomal Storage Diseases
-----------------------------------------------------------------------

In certain infectious diseases such as HIV, tuberculosis and leishmaniasis, the macrophage serves a special function as reservoir for the pathogen. Specific targeting of macrophages with agents toxic to the infectious substance may increase the therapeutic index and enable eradication of the pathogen \[[@B12-membranes-05-00228]\]. In leishmaniasis, the macrophage hosts the pathogen, and a liposomal formulation of the anti-leishmaniasis drug Amphotericin B is on the market for treatment of leishmaniasis. Although the liposomal formulated drug exhibits a higher therapeutic index than free drug, there are still severe adverse effects. Higher macrophage selectivity could be a way of improving the efficacy \[[@B13-membranes-05-00228]\].

Gaucher's disease is a lysosomal storage disease caused by lack of functional expression of the enzyme β-glucocerebrosidase in macrophage lysosomes. The disease can be treated to some extent by enzyme replacement therapy using a mannosylated version of the β-glucocerebrosidase, which owing to this carbohydrate modification is taken up through the mannose-receptor, predominantly in macrophages \[[@B14-membranes-05-00228]\].

2. Using CD163 for Macrophage Targeting of Small Molecules
==========================================================

2.1. CD163 Background
---------------------

CD163 was first described as a 130 kDa glucocorticoid-regulated surface protein in monocytes and macrophages \[[@B15-membranes-05-00228],[@B16-membranes-05-00228]\]. The function of the protein was unknown until it was identified as the scavenger receptor of the complex of haptoglobin (Hp) and hemoglobin (Hb) (Hp-Hb) formed after the lysis of red blood cells \[[@B17-membranes-05-00228]\]. Later, CD163 has been reported to bind human pathogenic bacteria \[[@B18-membranes-05-00228]\] and tumor necrosis factor-α-like weak inducer of apoptosis (TWEAK) \[[@B19-membranes-05-00228]\]. Furthermore, porcine CD163 has been shown to bind certain virus strains \[[@B20-membranes-05-00228],[@B21-membranes-05-00228]\].

2.2. CD163 Structure
--------------------

CD163 consists of nine SRCR domains, a transmembrane segment and a short C-terminal cytoplasmic tail \[[@B22-membranes-05-00228]\]. In addition to the membrane-bound CD163, a soluble version of CD163 (sCD163) is present in plasma \[[@B23-membranes-05-00228]\] due to cleavage of CD163 on the cell surface by the enzyme ADAM17 \[[@B24-membranes-05-00228]\]. Three splice variants of membrane-bound CD163 resulting in three isoforms with different cytoplasmic tails have been described \[[@B22-membranes-05-00228],[@B25-membranes-05-00228],[@B26-membranes-05-00228]\]. All three variants have the capacity to endocytose Hp-Hb, but owing to the expression level and subcellular localization, the variant with the shortest cytoplasmic tail seems responsible for the majority of the ligand clearance in man \[[@B27-membranes-05-00228]\].

The nine SRCR domains of CD163 belongs to an ancient extracellular domain family \[[@B28-membranes-05-00228]\], the bona fide domain consists of approximately 100 amino acids residues and it is found as a class A or B variant, which only differ by the presence of an additional disulfide bridge in the class B variant \[[@B29-membranes-05-00228]\]. Whereas the class B SRCR domains are encoded in one exon and strictly found in vertebrates, the class A are encoded by two exons and found in all phyla from metazoa \[[@B30-membranes-05-00228]\]. Furthermore, class A repeats are usually seen as single domains in mosaic proteins in contrast to the class B repeats, which appear as multirepeat SRCR clusters in the extracellular domains of membrane proteins \[[@B28-membranes-05-00228]\]. Concordantly, the SRCR domains of CD163 are belonging to class B.

SRCR domains contain consensus calcium binding sites that coordinate acidic amino acids for electrostatic interactions with ligands \[[@B29-membranes-05-00228]\], as is the case for many other extracellular domains designed for molecular interactions, like LDLR A repeats, CUB domains and others \[[@B31-membranes-05-00228]\]. Four of the SRCR domains of CD163 (domains 2, 3, 7 and 9) have conserved consensus calcium binding sites, whereas domain 5 has a potentially/semi-conserved site. The other four SRCR of CD163 domains have at least one non-conservative mutation of essential residues in the consensus calcium binding positions \[[@B32-membranes-05-00228]\].

2.3. CD163 Function
-------------------

The CD163-mediated macrophage clearance of the Hp-Hb complex from circulation is a well-documented mechanism \[[@B17-membranes-05-00228]\]. This scavenger receptor function prevents the toxic effect of the heme molecule. The Hp-Hb complex is formed after the release of hemoglobin from erythrocytes during intravascular hemolysis. Under physiological conditions, this pathway may account for approximately 10% of the red blood cell degradation, corresponding to 0.5--1 gram of hemoglobin being cleared by CD163 per day \[[@B33-membranes-05-00228],[@B34-membranes-05-00228],[@B35-membranes-05-00228]\]. However, during excessive pathological hemolysis CD163-mediated hemoglobin removal may increase greatly. The pathway should therefore be seen as an important defense mechanism to prevent the toxic effects of heme and hemoglobin during hemolytic disease. The defense is further enforced by the CD91-mediated uptake of heme-hemopexin complexes, when heme is released during excessive hemolysis and Hp depletion \[[@B36-membranes-05-00228]\].

The Hp-Hb complex is very tightly associated with an apparent association constant of 10^15^ M in humans \[[@B37-membranes-05-00228]\], making it the strongest protein--protein interaction described in plasma. The crystal structure of porcine and human Hp-Hb has been determined \[[@B38-membranes-05-00228]\]. A loop region of Hp previously identified as being involved in the interaction with CD163 \[[@B39-membranes-05-00228]\] is localized near the Hb α-chain in the complex, and Hb binding is suggested to stabilize the loop orientation \[[@B38-membranes-05-00228]\]. The binding to CD163 involves SRCR domain 2 and 3 of CD163 \[[@B40-membranes-05-00228]\] and is strictly dependent on calcium \[[@B41-membranes-05-00228]\].

After internalization in the macrophage, Hp-Hb is released from CD163 in the endosome \[[@B25-membranes-05-00228]\] owing to the lowering of pH and calcium concentration \[[@B41-membranes-05-00228]\], a common mechanism that ensures ligand dissociation after internalization of ligand-receptor pairs \[[@B31-membranes-05-00228]\]. The macrophage, which is also responsible for the erythrophagocytosis of outdated red blood cells, has the enzymatic machinery for subsequent degradation of Hb in the lysosome. Heme is released and diffuses into the cytoplasm where it is degraded to biliverdin, CO and iron by heme-oxygenases, whereupon biliverdin is further degraded to bilirubin. By means of albumin, the bilirubin is then transported to the hepatocytes for conjugation and secretion into the bile \[[@B42-membranes-05-00228]\]. Biliverdin, bilirubin and CO are reported to exert anti-inflammatory effects \[[@B43-membranes-05-00228]\] leading to a localized anti-inflammatory response \[[@B42-membranes-05-00228]\] partly mediated by IL-10. This in turn up-regulates both CD163 and hemeoxygenase-1 thus further potentiating Hb uptake \[[@B29-membranes-05-00228],[@B44-membranes-05-00228]\].

During conditions of excessive intravascular hemolysis Hp can be depleted from the blood, and in this cases free Hb may also be taken up by CD163 due to a weak affinity for CD163 \[[@B45-membranes-05-00228]\]. There seems to be important species differences on this point. In mice for instance, free Hb binds with a higher affinity and the Hp complex formation has apparent only minor effect on the affinity for murine CD163 of Hb \[[@B46-membranes-05-00228]\]. In CD163 gene knock-out mice, Hb is cleared only slightly slower than in normal mice, albeit with a one-phase decay as opposed to a two-phase decay in wild-type mice, and Hp-Hb complex formation prior to injection does not affect pharmacokinetics in either wild-type or knock-out mice \[[@B46-membranes-05-00228]\]. In rats, an Hp-independent mechanism of Hb clearance has also been described \[[@B47-membranes-05-00228]\]. In conclusion, this shows crucial differences between man and rodents in Hb scavenging. In rodents, the role of Hp seems primarily to prevent renal filtration and prevent oxidative modification by Hb \[[@B48-membranes-05-00228],[@B49-membranes-05-00228]\] rather than facilitating CD163-mediated clearance.

In addition to its function in Hb scavenging, CD163 has been reported to be acting as an erythrocyte adhesion molecule in rats \[[@B50-membranes-05-00228]\]. Together with at least four other macrophage surface molecules, CD163 mediates adherence of erythroblasts in development to macrophages in the so-called erythroblastic island \[[@B51-membranes-05-00228]\], thereby enhancing efficiency of late state erythropoiesis \[[@B52-membranes-05-00228]\].

CD163 is also reported to internalize the TNF-superfamily cytokine TWEAK \[[@B19-membranes-05-00228]\] and in this way the receptor is proposed to prevent the exertion of the pro-inflammatory signaling function of TWEAK in atherosclerosis \[[@B53-membranes-05-00228]\]. Interestingly, soluble TWEAK and soluble CD163 seem to be inversely correlated in inflammatory cardiovascular disease, and the ratio between the two markers may increase accuracy in prediction of long-term survival in patients with peripheral arterial disease \[[@B54-membranes-05-00228]\].

Finally, CD163 has been reported to bind pathogens such as certain vira and bacteria (*S. mutans*, *S. aureus*, and *E. coli*). Binding to CD163 on the surface of monocytic cells induces pro-inflammatory signaling, as evidenced by an increase in TNF release *in vitro* \[[@B18-membranes-05-00228]\]. Based on this finding, CD163 has been suggested to have an innate immune related bacterial sensing function mediating a local immune response \[[@B18-membranes-05-00228]\]. In addition, it has been shown that *S. aureus* induces shedding of CD163 from the monocyte, with sCD163 subsequently being able to bind to the bacteria trough fibronectin bound on the bacterial surface. The surface binding of fibronectin is an integral part of the pathomechanism of *S. aureus*, and CD163 binding might thereby protect against *S. aureus* infection by enhancing phagocytosis of the bacteria \[[@B55-membranes-05-00228]\].

In addition to binding some bacteria, CD163 has been reported to bind virus particles in pigs. Contrary to the perceived role of human CD163 in defense against the pathogens, CD163 seems to promote the cellular entry of the virus. This is the case in the infection with the African swine fever virus (ASFV) and porcine reproductive and respiratory syndrome virus (PRRSV) \[[@B56-membranes-05-00228]\]. For ASFV, the role of CD163 is to act as a point of attachment for subsequent macrophage internalization leading to infection of the monocyte/macrophage, an interaction that can be inhibited by a specific CD163 monoclonal antibody \[[@B20-membranes-05-00228]\]. For PRRSV, the role of CD163 seems related to virus un-coating in the early endosome following sialoadhesin-mediated internalization, thus rendering the virus infective \[[@B21-membranes-05-00228],[@B57-membranes-05-00228]\]. A central region of CD163, mainly consisting of SRCR domain number 5, which is different from the Hp-Hb binding region, is involved in the interaction with the virus \[[@B58-membranes-05-00228]\].

Interestingly, human monocytes/macrophages have been reported to be more permissive to HIV infection *in vitro* after substance P-mediated increase of CD163 expression, and HIV infection of monocytes can be inhibited by Hp-Hb. However, the data needs further conformation \[[@B59-membranes-05-00228]\].

2.4. CD163 Expression
---------------------

CD163 is expressed only in cells of the monocytic-macrophage lineage, and with increasing expression as monocytes maturate into macrophages. The expression of CD163 is especially high in macrophages in liver (Kupffer cells), red pulp of the spleen, the lung and the bone marrow \[[@B60-membranes-05-00228]\]. Other resident monocyte-derived cells such as Langerhans \[[@B61-membranes-05-00228]\] and dendritic cells \[[@B62-membranes-05-00228]\] do not, or only weakly, express CD163.

Varying levels of CD163 expression on monocytes and macrophages have been reported in literature and this confusing discrepancy is due to different features of the antibodies used in the different studies. For instance, binding of some antibodies is sensitive to EDTA used as anti-coagulant; others recognize CD163 epitopes that are less accessible when the receptor is inserted in the membrane \[[@B32-membranes-05-00228]\].

Culturing of monocytes *in vitro* greatly increases the expression level of CD163 \[[@B16-membranes-05-00228]\]. Further, CD163 expression level can be up-regulated by stimulation with a range of reagents affecting the maturation of monocytes into specific macrophage subtypes. *In vitro*, CD163 expression on monocytes (and maturated macrophages) can be upregulated by heme, Hb, glucocorticoids, IL-6, and IL-10, whereas lipopolysaccharide (LPS), TNF, IL-4, and granulocyte-macrophage colony stimulating factor down-regulate expression \[[@B63-membranes-05-00228]\].

For many years, CD163 has been seen as a classical marker for human M2-macrophages, also designated "alternatively activated" macrophages, albeit this is an inherent *in vitro* distinction \[[@B64-membranes-05-00228]\] because *in vivo* the macrophage has a rather plastic phenotype that responds to the many local and different stimulations. CD163 expression on M2-like macrophages has been shown in a range of inflamed tissues in both chronic and acute inflammation \[[@B63-membranes-05-00228]\]. [Table 1](#membranes-05-00228-t001){ref-type="table"} displays a list of inflammatory diseases where CD163 expressing macrophages have been identified at the site of inflammation, and for which cytokine signaling is part of the disease pathomechanism. In addition, high levels of sCD163 can be detected in plasma in a wide range of inflammatory diseases and most likely reflects a general increase of CD163 expression at sites of inflammation \[[@B65-membranes-05-00228]\]. Increased levels of CD163 expressing macrophages are also found in the microglia of Alzheimer's disease patients' frontal and occipital cortices and in the brainstems of Parkinson's disease patients, the CD163 expressing cells could either be resident microglial macrophages or infiltration of the brain by systemic macrophages \[[@B66-membranes-05-00228]\]. In HIV patients with neurocognitive impairment, the macrophages at the sites of neuroinflammation are activated and exhibit increased CD163 expression \[[@B67-membranes-05-00228]\]. In rhesus macaque monkeys, it has been shown that the activation and increase in CD163 expression is caused by macrophage colony-stimulating factor \[[@B68-membranes-05-00228]\]. Further, in SIV infected monkeys, increased numbers of CD163+ macrophages in the heart is correlated with increased cardiac fibrosis and myocardial degeneration \[[@B69-membranes-05-00228]\].

membranes-05-00228-t001_Table 1

###### 

Inflammatory indications with up-regulation of CD163(+) macrophages at site of inflammation, as evidenced by studies of patient samples.

  Inflammatory Conditions with Up-Regulation of CD163 Macrophages at Site of Inflammation and Involvement of Pro-inflammatory Cytokines in Pathogenesis                                                                                                                               
  ------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- --------------------------------------- -------------------------------------------------------------------------------------------------------------
  Acute and infectious inflammations                                                                                                                      Chronic sterile inflammations                                                                                               
  Indication                                                                                                                                              Reference                                                                           Indication                              Reference
  Acute alcoholic hepatitis                                                                                                                               \[[@B70-membranes-05-00228],[@B71-membranes-05-00228]\]                             Non-alcoholic steatohepatitis (NASH)    \[[@B72-membranes-05-00228],[@B73-membranes-05-00228]\]
  Acute viral hepatitis                                                                                                                                   \[[@B74-membranes-05-00228]\]                                                       Rheumatoid arthritis                    \[[@B75-membranes-05-00228],[@B76-membranes-05-00228],[@B77-membranes-05-00228],[@B78-membranes-05-00228]\]
  Sepsis                                                                                                                                                  \[[@B79-membranes-05-00228]\]                                                       Psoriatic arthritis                     \[[@B80-membranes-05-00228]\]
  Hemophagocytic syndrome                                                                                                                                 \[[@B81-membranes-05-00228],[@B82-membranes-05-00228]\]                             Giant cell arteritis                    \[[@B83-membranes-05-00228]\]
  Celiac disease                                                                                                                                          \[[@B84-membranes-05-00228]\]                                                       Osteoarthritis                          \[[@B85-membranes-05-00228],[@B86-membranes-05-00228]\]
  Acute kidney failure                                                                                                                                    \[[@B87-membranes-05-00228],[@B88-membranes-05-00228]\]                             Graft *versus* host disease             \[[@B89-membranes-05-00228]\]
  Rejected kidney allografts                                                                                                                              \[[@B90-membranes-05-00228]\]                                                       Inflammatory bowel disease              \[[@B91-membranes-05-00228],[@B92-membranes-05-00228],[@B93-membranes-05-00228]\]
  Atherosclerosis                                                                                                                                         \[[@B53-membranes-05-00228],[@B94-membranes-05-00228],[@B95-membranes-05-00228]\]   Multiple sclerosis                      \[[@B96-membranes-05-00228],[@B97-membranes-05-00228]\]
  HIV                                                                                                                                                     \[[@B67-membranes-05-00228]\]                                                       Sarcoidosis                             \[[@B98-membranes-05-00228],[@B99-membranes-05-00228]\]
                                                                                                                                                                                                                                              Scleroderma                             \[[@B100-membranes-05-00228],[@B101-membranes-05-00228],[@B102-membranes-05-00228]\]
                                                                                                                                                                                                                                              Chronic obstructive pulmonary disease   \[[@B103-membranes-05-00228]\]
                                                                                                                                                                                                                                              Systemic lupus erythematosus            \[[@B104-membranes-05-00228],[@B105-membranes-05-00228]\]
                                                                                                                                                                                                                                              Alzheimer's disease                     \[[@B66-membranes-05-00228]\]

Tumor-associated macrophages also exhibit a prominent CD163 expression the level of CD163 expression is linked to poor survival in a range of tumors, as listed in [Table 2](#membranes-05-00228-t002){ref-type="table"}.

membranes-05-00228-t002_Table 2

###### 

Cancer indications with proven negative correlation between tumor-associated macrophage CD163 expression and survival.

  Cancers with Link between Tumor-Associated Macrophage CD163 Expression and Survival   
  ------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------
  Cancer tissue                                                                         Reference
  Myeloma                                                                               \[[@B106-membranes-05-00228]\]
  T-cell lymphomas                                                                      \[[@B107-membranes-05-00228],[@B108-membranes-05-00228]\]
  Hodgkin's lymphoma                                                                    \[[@B109-membranes-05-00228],[@B110-membranes-05-00228],[@B111-membranes-05-00228]\]
  Follicular lymphoma                                                                   \[[@B112-membranes-05-00228]\]
  Meningioma                                                                            \[[@B113-membranes-05-00228],[@B114-membranes-05-00228]\]
  Glioma                                                                                \[[@B115-membranes-05-00228]\]
  Epithelial ovarian cancer                                                             \[[@B114-membranes-05-00228],[@B116-membranes-05-00228]\]
  Non-small cell lung cancer                                                            \[[@B117-membranes-05-00228]\]
  Pancreatic cancer                                                                     \[[@B118-membranes-05-00228]\]
  Stroma of breast cancer                                                               \[[@B119-membranes-05-00228],[@B120-membranes-05-00228]\]
  Stroma of bladder cancer                                                              \[[@B121-membranes-05-00228]\]
  Oral squamous cell cancer                                                             \[[@B122-membranes-05-00228],[@B123-membranes-05-00228]\]
  Colorectal cancer                                                                     \[[@B124-membranes-05-00228]\]
  Papillary renal cell carcinoma                                                        \[[@B125-membranes-05-00228]\]
  Clear cell renal cell carcinoma                                                       \[[@B126-membranes-05-00228]\]
  Endometrial adenocarcinoma                                                            \[[@B127-membranes-05-00228]\]
  Intrahepatic cholangiocarcinoma                                                       \[[@B128-membranes-05-00228]\]
  Uveal melanoma                                                                        \[[@B129-membranes-05-00228]\]
  Cutaneous malignant melanoma                                                          \[[@B130-membranes-05-00228],[@B131-membranes-05-00228]\]

In addition to expression on monocyte-derived cells, expression of CD163 and other macrophages antigens on cancer cells have been described \[[@B132-membranes-05-00228]\]. It has therefore been hypothesized that tumor cells can fuse with macrophages, and this has now been documented in *in vitro* studies \[[@B133-membranes-05-00228],[@B134-membranes-05-00228],[@B135-membranes-05-00228],[@B136-membranes-05-00228],[@B137-membranes-05-00228]\]. Such fusion cells grow slower *in vitro* \[[@B138-membranes-05-00228]\], whereas *in vivo* they grow faster and exhibit higher metastatic potential compared to normal cancer cells \[[@B136-membranes-05-00228],[@B139-membranes-05-00228],[@B140-membranes-05-00228]\]. CD163 expression on the cancer cells has been demonstrated in 48% of breast cancer biopsies \[[@B141-membranes-05-00228]\], 39% of bladder cancer biopsies \[[@B135-membranes-05-00228]\], 23% of rectal cancer biopsies \[[@B142-membranes-05-00228]\] and 20% of colorectal cancer biopsies \[[@B124-membranes-05-00228]\]. In all the studies expression, the level of CD163 on the cancer cells correlated with poor survival \[[@B143-membranes-05-00228]\].

Finally, CD163 expression has been described on primary tumors of monocytic origin, such as histiocytic sarcomas \[[@B144-membranes-05-00228]\], and certain subtypes (M4/M5) of acute myeloid leukemia \[[@B145-membranes-05-00228],[@B146-membranes-05-00228]\].

2.5. CD163 as a Target for Rapid Internalization of Vehicles
------------------------------------------------------------

CD163 seems to be an ideal target for intracellular delivery of drugs to macrophages, because of its highly selective expression in the tissue of interest and its function as a constitutive endocytotic receptor \[[@B147-membranes-05-00228],[@B148-membranes-05-00228]\]. The rapid internalization of ligands binding to CD163 ensures minimum systemic exposure of the drug. The rapid clearance is evidenced by injections of monoclonal antibodies in animals. In pigs, a humanized CD163 monoclonal antibody injected at a dose of 2 mg/kg exhibits a plasma half-life in the range of 5--8 min \[[@B149-membranes-05-00228]\]. For a CD163 monoclonal antibody injected at a dose of 2.4 mg/kg in rats, 50% of the dose is cleared after 20 min \[[@B150-membranes-05-00228]\]. An i.v.-injected ^68^Ga-labeled CD163 antibody showed fast clearance and rapid accumulation to macrophage-rich tissues by PET-scanning. The majority of the dose was taken up by the liver, whereas the spleen exhibited the highest dose relative to organ weight \[[@B151-membranes-05-00228]\]. In rat liver *in vivo*, the ^68^Ga-labeled CD163 antibody was specifically binding to and internalized in Kupffer cells \[[@B151-membranes-05-00228]\]. Furthermore, in arthritic rats there was an increased deposition of antibodies in the inflamed paws of the animals compared to healthy rats.

So-called stealth liposomes with reduced uptake in phagocytosing cells can be created by PEGylation of the liposome surface \[[@B152-membranes-05-00228]\] with polyethylene glycol (PEG). Using a PEG molecule as linker, the surface of the liposome can be further modified, for instance with monoclonal antibodies (mAbs) ensuring liposome binding to specific cell type antigens \[[@B153-membranes-05-00228]\]. PEGylated stealth liposomes linked with CD163 antibodies on the surface have also shown rapid clearance in rats and accumulation in macrophage-rich tissues \[[@B154-membranes-05-00228]\]. Liposomes with human Hb as the targeting moiety instead of a CD163 antibody also exhibited specific uptake in CD163-expressing macrophages \[[@B155-membranes-05-00228]\]. Targeted liposomes enables incorporation of a wider range of drugs than can be achieved using antibody drug conjugates (ADCs) and further, more drugs can be delivered per cell per unit taken up compared to ADCs.

The elevated plasma concentration of sCD163 in patients with inflammation might theoretically compete for ADC binding to CD163. However, the sCD163 in plasma is low compared to the expression level of membrane-bound CD163, which has the further advantage of increasing avidity by being cross-linked by bi- or multivalent ligands. Moreover, in a therapeutic setting the therapeutic dose of antibodies may neutralize the sCD163 after the first injection of ADC.

In accordance with an endocytic uptake of antibody-drug complexes via CD163, cellular uptake studies have shown that antibody and drug co-localize in intracellular compartments corresponding to endosomes or lysosomes after 30 min. These studies with dexamethasone-conjugated antibody against rat CD163 have taken advantage of an esterase degradable linker enabling intracellular release of dexamethasone in the endosome/lysosome. The segregation of antibody and drug was visible after 2 h \[[@B150-membranes-05-00228]\]. Similar uptake kinetics has been observed with CD163-directed liposomes \[[@B154-membranes-05-00228]\].

A drug delivered to the macrophage endosome/lysosome can then be released and, given that it has the right properties in terms of membrane permeability, diffuse passively into the cytosol where it exerts its function. The clearance of the CD163 binding vehicle, due to clearance and uptake in macrophages, is fast, so it is preferable to have a prolonged (e.g., drugs regulating translation/transcription such as glucocorticoids \[[@B156-membranes-05-00228],[@B157-membranes-05-00228]\] or siRNA \[[@B158-membranes-05-00228]\]) or an irreversible drug effect (e.g., cytotoxins) on the cell. A CD163-targeting drug will be systemically distributed to monocytes and macrophages of perfused organs. However, a targeting vehicle will probably not be able to cross the blood--brain barrier and reach the CD163-expressing microglia. Nevertheless, the drugs could anyway have an effect by targeting circulating monocytes prior to their migration over the blood--brain barrier.

2.6. Effect of Targeting Macrophages with Small Molecule Drugs Using CD163
--------------------------------------------------------------------------

The CD163-targeting of glucocorticoid has a tremendous effect as shown *in vitro* and *in vivo* \[[@B149-membranes-05-00228],[@B150-membranes-05-00228],[@B159-membranes-05-00228]\]. The *in vivo* anti-inflammatory effect of anti-CD163 IgG-dexamethasone in rats \[[@B150-membranes-05-00228]\] is comparable to a 50-fold higher dose of free dexamethasone in terms of inhibiting LPS-induced cytokine production. This study also shows that by the targeting to CD163 with low dose dexamethasone, serious side effects (e.g., reduced body weight, lymphocytes apoptosis and suppression of endogenous cortisol production) of the equipotent high doses of free dexamethasone are avoided \[[@B150-membranes-05-00228]\]. The anti-inflammatory equipotent 50-fold lower dose of dexamethasone (0.02 mg/kg) as a CD163 targeting ADC does not affect any of these systemic parameters compared to vehicle treatment \[[@B150-membranes-05-00228]\].

The findings in rats have been corroborated by a similar study in a pig endotoxemia model \[[@B149-membranes-05-00228]\]. In this study the anti-CD163-dexamethasone ADC was based on a humanized CD163 mAb linked with dexamethasone trough the same esterase-sensitive linker as used in rats \[[@B149-membranes-05-00228]\]. The effect on cytokine production was again comparable to a 50-fold higher dose of free dexamethasone (0.02 *vs.* 1 mg/kg), and again adverse systemic effects of the ADC was not observed, as evidenced by unchanged cortisol and ACTH levels compared to vehicle treatment.

In addition to modulating macrophage phenotype, direct eradication of macrophages may also be of interest, for instance in reducing tumor growth by removing tumor-associated macrophages. Eradication of macrophages including tumor-associated macrophages using clodronate-liposomes has accordingly been shown to slow the growth of a chemically induced lung tumor and a cutaneous T-cell lymphoma in mice \[[@B160-membranes-05-00228],[@B161-membranes-05-00228]\] as well as to inhibit tumor angiogenesis in murine cancer models \[[@B162-membranes-05-00228],[@B163-membranes-05-00228]\]. Further, in these mice studies macrophage depletion for up to five weeks did not reveal serious acute adverse effects. Macrophage depletion using clodronate liposomes has also been attempted in dogs for treatment of hemolytic anemia \[[@B164-membranes-05-00228]\], soft tissue sarcoma \[[@B165-membranes-05-00228]\] and malignant histiocytosis \[[@B166-membranes-05-00228]\]. In these studies, temporary macrophage depletion was induced for 2--8 weeks, and no serious adverse effects were observed. However, in pigs, depletion of aveolar macrophages rendered the pig more sensitive to human H1N1 influenza virus, causing a mortality rate of 40% \[[@B167-membranes-05-00228]\]. Similarly, impaired aveolar macrophage function has been linked to increased mortality to primary respiratory syncytial virus bronchiolitis, as evidenced by studies of human lung tissue and confirmed by murine studies \[[@B168-membranes-05-00228]\]. This clearly points to potential adverse effects of macrophage depletion. Clodronate liposomes are not only killing macrophages but also dendritic cells \[[@B168-membranes-05-00228]\]. Specific targeting of CD163 expressing cells should prevent depletion of dendritic cells, thus potentially further limit the adverse effects of the treatment. Linking a CD163-antibody to Doxil^TM^, a registered liposomal doxorubicin formulation against Kaposi's sarcoma, has been shown to specifically kill CD163-expressing cells \[[@B154-membranes-05-00228]\]. Further studies using this approach in animal cancer models are in progress and may further validate specific macrophage-targeting as a viable approach for cancer treatment.

3. Other Attempts at Targeting Macrophages in Inflammation and Cancer
=====================================================================

The targeting of macrophages with a vehicle can be also achieved by other active targeting means \[[@B12-membranes-05-00228],[@B169-membranes-05-00228]\].

By conjugating a 29 amino acid peptide derived from rabies virus glycoprotein to TNF-silencing siRNA, active targeting and uptake in macrophages and dendritic cells have been demonstrated \[[@B170-membranes-05-00228]\]. The construct lowered LPS-induced TNF production by macrophages and dendritic cells both *in vitro* and *in vivo* \[[@B171-membranes-05-00228]\].

Macrophage targeting approaches also include the linking of drugs with specific carbohydrates that recognize lectin receptors on the macrophage surface. One attempt has been targeting of TNF-silencing siRNA by linking it to *β*-1,3-glucan schizophyllan that binds to dectin-1 on the surface on antigen presenting cells. This accomplished binding to and internalization in antigen-presenting cells, including macrophages \[[@B172-membranes-05-00228]\]. The construct was taken up in the Kupffer cells of the liver, and it protected mice from hepatitis induced by the combination of LPS and D-galactosamine \[[@B172-membranes-05-00228]\].

Another approach using carbohydrates has been to target the mannose receptor. As mentioned earlier in this review, this approach is used for targeting β-glucocerebrosidase for treatment of the lysosomal storage disease Gaucher's disease. By conjugating dexamethasone to mannosylated human serum albumin, uptake in Kupffer cells has been demonstrated. However, in this study, there was also an increase in unexplained liver fibrosis. The effect seemed to be related to the mannosylation of serum albumin, because mannosylated serum albumin without dexamethasone also caused increased liver fibrosis \[[@B173-membranes-05-00228]\].

Mannosylated liposomes have also been tried and, when loaded with dexamethasone and administered intratracheally in rats, they were about five-fold more effective than free dexamethasone \[[@B174-membranes-05-00228]\]. At a dose of 0.5 mg/kg, the liposomes inhibited cytokine signaling and lung damage in LPS-induced lung inflammation in rats \[[@B175-membranes-05-00228]\]. Though encouraging, the dexamethasone dose used is still quite high, and might, even if administered systemically, still cause severe adverse effects. Further, the mannose receptor is not expressed selectively on macrophages, but also on dendritic cells and a range of non-vascular endothelia including hepatic, splenic, lymphatic, endothelia, as well as on kidney cells, mesangial cells, and trachea smooth muscle cells \[[@B176-membranes-05-00228]\], leading to potential off-target uptake in other cell types. In this perspective, the mannose receptor seems less favorable for specific delivery to macrophages.

As an alternative to active targeting, macrophages can be hit by passive targeting as shown in other studies targeting with liposomal glucocorticoids. Passive targeting using liposomes without targeting moiety is hampered by not being macrophage-specific, regardless of whether stealth liposomes or naked liposomes are used, with up-take in other cell types such as hepatocytes, endothelial and epithelial cells, neutrophils, dendritic cells, B-cells, M-cells and subtypes of T-cells \[[@B169-membranes-05-00228]\]. Several studies of the effect of glucocorticoids in liposomes on animal models of inflammation have been published \[[@B177-membranes-05-00228]\]. A study in mice with autoimmune-induced arthritis (AIA) revealed that in the arthritic joints, liposomes were primarily taken up by macrophages and by early osteoclasts precursors. This was reflected by reduced arthritis and bone erosion when mice were treated with liposomes with prednisolone \[[@B178-membranes-05-00228]\].

Whether liposomes are used in active or passive targeting, the drug cargo should preferably be located inside the liposome and not in the liposomal membrane in order to increase the stability of the liposomes and minimize drug leakage. Further, this allows the number of drug molecules per liposome to be increased allowing a reduction in the number of liposomes injected, and thereby a reduction of the risk of adverse effects to the liposome injection *per se*. This was achieved using the so-called "remote loading technique" to encapsulate prednisolone hemisuccinate and betamethasone hemisuccinate in small (80 nm) PEGylated liposomes \[[@B179-membranes-05-00228],[@B180-membranes-05-00228]\]. The liposomes exhibited increased plasma retention time and an increased effect in AIA rats compared to free glucocorticoid both in early and late development of disease \[[@B180-membranes-05-00228]\]. Further, the localization of the liposomes in the paws was approximately doubled in AIA rats compared to control animals \[[@B180-membranes-05-00228]\]. These liposomes have shown similar effect when being administrated subcutaneously, where only approximately 40% of the injected dose reached circulation \[[@B181-membranes-05-00228]\]. In a murine experimental autoimmune encephalomyelitis model of multiple sclerosis, this liposomal glucocorticoid was more efficient than a five times higher dose of non-liposomal glucocorticoid \[[@B179-membranes-05-00228]\].

Stealth liposomes loaded with dexamethasone have been tested in models of acute and chronic chemically induced liver injury in mice, and showed that 1 mg/kg of liposome-formulated dexamethasone inhibited liver fibrosis compared to both vehicle and free dexamethasone. However, the effect appeared mainly to be owing to T-cell depletion after uptake of the liposomes, and only to a limited extent to a re-polarization effect on macrophages \[[@B182-membranes-05-00228]\].

4. Concluding Remarks
=====================

Macrophage cytokine production is of importance in the propagation of a range of inflammatory indications. The production of these cytokines has been modified through active and passive targeting of macrophages. A straightforward way is to specifically target glucocorticoids to macrophages to re-polarize the macrophage to an anti-inflammatory phenotype. Glucocorticoids are very potent and efficacious anti-inflammatory drugs. However, they also exert strong systemic adverse effects since they can modulate transcription of multiple genes in virtually all cells of the body.

This requires a more strict selectivity of the cellular targeting to reduce the adverse effects of glucocorticoids, compared to for instance targeting of siRNA, which only directly affects a single gene, which may only be expressed in a limited range of cells. Using both passive and active targeting of dexamethasone to macrophages increases in efficacy have been achieved, but the dose used was still relatively high and able to cause systemic adverse effects. This was also the case when the mannose receptor was used as target, even though it is expressed at a high level on macrophages, since the macrophage expression specificity is relatively limited. More macrophage-specific targets should thus be used in order to obtain an even larger reduction in the dose of glucocorticoid needed to exert an anti-inflammatory effect.

Specific macrophage targeting can be obtained by targeting the macrophage receptor CD163. Targeting dexamethasone to macrophages using an anti-CD163-dexamethasone ADC increased the anti-inflammatory effect of dexamethasone in terms of inhibition of cytokine production in primitive inflammation models by approximately 50-fold.

Alteration of macrophage activity using CD163-specific targeting with anti-inflammatory drugs could in principle be relevant in a range of inflammatory indications as listed in [Table 1](#membranes-05-00228-t001){ref-type="table"}. In order to further increase the effect of targeting CD163-macrophages, initial studies could be conducted in indications affecting assessable organs with a high number of macrophages \[[@B183-membranes-05-00228],[@B184-membranes-05-00228]\].

Specific targeting of macrophages with dexamethasone may not entirely wipe out side effects. It is reasonable to assume that adverse effects must fall within a subset of the adverse effects already observed for systemic treatment with glucocorticoids. Most notably, a change in macrophage activation may increase risk of infection, although the B- and T-cell response should still function. Activation of latent tuberculosis infection could thus be a risk, as is the case for treatment with biological TNF-inhibitors \[[@B185-membranes-05-00228]\]. However, more is still to be learned about the long-term effect on changing and reducing macrophage activity.

In conclusion, CD163 is a promising target for specific delivery of small drugs into the macrophage, and it has been validated as a target in animal models.
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